- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.01. | Arch Biopartners Inc: Arch receives OK to proceed with phase II LSALT trial | 1 | Stockwatch | ||
| 08.01. | Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI) | 60 | GlobeNewswire (Europe) | TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network Research Ethics... ► Artikel lesen | |
| 21.11.24 | Arch Biopartners Inc: Arch Biopartners 250,323-share private placement | 2 | Stockwatch | ||
| 11.11.24 | Arch Biopartners Inc: Arch Biopartners begins patient dosing for LSALT trial | 1 | Stockwatch | ||
| ARCH BIOPARTNERS Aktie jetzt für 0€ handeln | |||||
| 11.11.24 | Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury | 79 | GlobeNewswire (Europe) | TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in... ► Artikel lesen | |
| 16.10.24 | Arch Biopartners Inc: Arch Biopartners arranges $450,000 private placement | 1 | Stockwatch | ||
| 16.10.24 | Arch Biopartners Arranges Non-Brokered Private Placement | 1 | GlobeNewswire (USA) | ||
| 03.10.24 | Arch Biopartners Inc: Arch Biopartners closes units-for-debt settlement | 2 | Stockwatch | ||
| 03.10.24 | Arch Biopartners: Closes Units for Debt Settlement | 1 | GlobeNewswire (USA) | ||
| 26.09.24 | Arch Biopartners Inc: Arch Biopartners to issue units to settle debt | 3 | Stockwatch | ||
| 26.09.24 | Arch Biopartners: Units for Debt Settlement | 2 | GlobeNewswire (USA) | ||
| 11.09.24 | Arch Biopartners Inc: Arch Biopartners receives Alberta OK for phase II trial | 1 | Stockwatch | ||
| 11.09.24 | Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI) | 1 | GlobeNewswire (USA) | ||
| 07.08.24 | Arch Biopartners Inc: Arch Biopartners 400,000-share private placement | 1 | Stockwatch | ||
| 02.08.24 | Arch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins | 100 | GlobeNewswire (Europe) | Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique... ► Artikel lesen | |
| 16.04.24 | Arch Biopartners: St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury | 397 | GlobeNewswire (Europe) | TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael's Hospital... ► Artikel lesen | |
| 18.03.24 | Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2 | 139 | GlobeNewswire (Europe) | British Medical Journal Open publishes paper detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients... ► Artikel lesen | |
| 15.03.24 | Arch Biopartners: University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury | 375 | GlobeNewswire (Europe) | TORONTO, March 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from the University of Calgary's... ► Artikel lesen | |
| 07.03.24 | Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury | 159 | GlobeNewswire (Europe) | TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 57,19 | 0,00 % | Tempus AI's Options Frenzy: What You Need to Know | ||
| EVOTEC | 8,580 | +5,66 % | BioTech - jetzt geht's los! 100 % Chancen für Evotec, BioNxt, Bayer, Formycon und Novo Nordisk! | Der DAX 40-Index erreichte in der letzten Woche mit 21.520 Punkten ein neues Allzeithoch. Das klingt auf den ersten Blick komisch, denn die Hälfte aller Werte krebst an mehrjährigen Tiefstständen. Zugpferde... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 54,73 | 0,00 % | Pre-market Movers: China Liberal Education, CARGO Therapeutics, Tectonic Therapeutic, Silexion Therapeutics, Banzai International | SANDY SPRINGS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green Tectonic Therapeutic, Inc. (TECX) is up over... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 13,670 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million | Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, up approximately 366% vs. Q4 2023 and 41% vs. Q3 2024Preliminary unaudited product... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,690 | 0,00 % | How Is The Market Feeling About Recursion Pharmaceuticals? | ||
| BIONTECH | 116,60 | +0,34 % | Nach Gates-Besuch: BioNTech-Aktie legt deutlich zu | Die Aktie von BioNTech hat am Donnerstag einen deutlichen Kurssprung hinlegen können. Unterstützung erhielt das Papier dabei vom Besuch des Microsoft-Gründers Bill Gates in dieser Woche. Zudem hat das... ► Artikel lesen | |
| MODERNA | 40,315 | -3,59 % | Moderna Aktie: Finanzen im Fokus | Der US-Pharmakonzern Moderna hat einen bedeutenden Vertrag für die Belieferung der Europäischen Union mit seinem COVID-19-mRNA-Impfstoff abgeschlossen. Die Vereinbarung, die sich über einen Zeitraum... ► Artikel lesen | |
| CG ONCOLOGY | 30,150 | -0,30 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates | - Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature... ► Artikel lesen | |
| CARGO THERAPEUTICS | 3,390 | 0,00 % | Safety Risk Sinks Cargo Therapeutics' Cancer Cell Therapy Prospect, Leading to 50% Staff Cut | ||
| 89BIO | 9,650 | +10,54 % | 89bio, Inc. - 8-K, Current Report | ||
| BB BIOTECH | 42,600 | +2,16 % | EQS-News: BB BIOTECH AG: Vorläufige Jahresergebnisse 2024 und Dividendenvorschlag | EQS-News: BB BIOTECH AG
/ Schlagwort(e): Jahresergebnis/Dividende
BB Biotech: Vorläufige Jahresergebnisse 2024 und Dividendenvorschlag
24.01.2025 / 07:00 CET/CEST
Für... ► Artikel lesen | |
| IMMUNOME | 10,510 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
| VIR BIOTECHNOLOGY | 10,290 | 0,00 % | Vir Biotechnology, Inc. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 22,320 | +3,14 % | Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? | ||
| AVIDITY BIOSCIENCES | 32,630 | +2,10 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen |
Das Unternehmen ARCH BIOPARTNERS INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCH BIOPARTNERS INC finden Sie auf Wallstreet Online.
